Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index; 26 of the 48 sources its claims cite were checked for support.

Hsp90 Governs Echinocandin Resistance in the Pathogenic Yeast Candida albicans via Calcineurin

Open access
Singh, Sheena D., Robbins, Nicole, Zaas, Aimee K., Schell, Wiley A., Perfect, John R., Cowen, Leah E. · 2009 · PLoS Pathogens

Abstract

Candida albicans is the leading fungal pathogen of humans, causing life-threatening disease in immunocompromised individuals. Treatment of candidiasis is hampered by the limited number of antifungal drugs whose efficacy is compromised by host toxicity, fungistatic activity, and the emergence of drug resistance. We previously established that the molecular chaperone Hsp90, which regulates the form and function of diverse client proteins, potentiates resistance to the azoles in C. albicans and in the model yeast Saccharomyces cerevisiae. Genetic studies in S. cerevisiae revealed that Hsp90's role in azole resistance is to enable crucial cellular responses to the membrane stress exerted by azoles via the client protein calcineurin. Here, we demonstrate that Hsp90 governs cellular circuitry required for resistance to the only new class of antifungals to reach the clinic in decades, the echinocandins, which inhibit biosynthesis of a critical component of the fungal cell wall. Pharmacological or genetic impairment of Hsp90 function reduced tolerance of C. albicans laboratory strains and resistance of clinical isolates to the echinocandins and created a fungicidal combination. Compromising calcineurin function phenocopied compromising Hsp90 function. We established that calcineurin is an Hsp90 client protein in C. albicans: reciprocal co-immunoprecipitation validated physical interaction; Hsp90 inhibition blocked calcineurin activation; and calcineurin levels were depleted upon genetic reduction of Hsp90. The downstream effector of calcineurin, Crz1, played a partial role in mediating calcineurin-dependent stress responses activated by echinocandins. Hsp90's role in echinocandin resistance has therapeutic potential given that genetic compromise of C. albicans HSP90 expression enhanced the efficacy of an echinocandin in a murine model of disseminated candidiasis. Our results identify the first Hsp90 client protein in C. albicans, establish an entirely new role for Hsp90 in mediating resistance to echinocandins, and demonstrate that targeting Hsp90 provides a promising therapeutic strategy for the treatment of life-threatening fungal disease.

Overview

CoChat Summary

## TL;DR

Hsp90 is required for *Candida albicans* tolerance to echinocandins, and this effect depends largely on calcineurin. Genetic or pharmacological impairment of Hsp90 or calcineurin made micafungin more effective in vitro and in a murine disseminated infection model.

## Key findings

  • In antifungal susceptibility and spotting assays, inhibiting Hsp90 with geldanamycin (GdA) or radicicol (RAD) “dramatically enhanced” sensitivity to micafungin (MF) in two strains, and comparable effects were seen with caspofungin (CS).
  • Compromising Hsp90 function made the tetO-HSP90/hsp90Δ strain hypersensitive to MF even without tetracycline, and restoring a wild-type HSP90 allele complemented both the reduced growth rate and MF hypersensitivity.
  • Inhibiting calcineurin with cyclosporin A (CsA) or FK506 abolished MF tolerance; deleting CNA1 or CNB1 also abrogated MF tolerance, while CRZ1 deletion caused only a partial loss of MF tolerance.
  • In the murine model, mice infected with the tetO-HSP90/hsp90Δ strain had significantly reduced kidney fungal burden than mice infected with wild-type HSP90 strain (P<0.05), and MF further reduced fungal burden in the tetO-HSP90/hsp90Δ group (P<0.001).

## Methods

  • The study combined pharmacological inhibition (GdA, RAD, CsA, FK506) and genetic perturbation (HSP90, CNA1, CNB1, CRZ1 mutants; tetO-HSP90/hsp90Δ; MAL2p-HSP90/hsp90Δ) in *C. albicans* and *S. cerevisiae*.
  • Antifungal tolerance was measured using modified broth microdilution MIC assays, checkerboard synergy assays, and spotting assays on liquid and solid media with MF and CS.
  • Mechanistic tests included β-galactosidase reporter assays for calcineurin activation, co-immunoprecipitation of tagged Hsp90 and Cna1, immunoblotting for protein levels, and a tail-vein murine disseminated candidiasis model with kidney CFU readout.

## Limitations

  • The paper explicitly notes that the basis for the different responses with micafungin and caspofungin on solid medium is unclear, and the response with anidulafungin “remains to be determined.”
  • The authors state that synergy between Hsp90/calcineurin inhibitors and MF was not observed for all echinocandin-resistant clinical isolates tested; of 14 FKS1 mutants, synergy was observed for 8.
  • Evidence on cidality was limited by MF-induced clumping, which made CFU counts inaccurate in the echinocandin killing assay; this is stated in the paper.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1371/journal.ppat.1000532

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Hsp90 plays a crucial role in echinocandin tolerance of Candida albicans. (A) Pharmacological inhibition of Hsp90 with GdA or RAD reduces MF tolerance of C. albicans laboratory strains in an MIC assay. Assays were done in synthetic defined medium at 30°C for 72 hours. Optical densities were averaged for duplicate measurements and normalized relative to MF-free controls (see colour bar). (B) Pharmacological inhibition of Hsp90 reduces MF tolerance on solid rich medium (YPD). Cells were spotted in fivefold dilutions (from 1×106 cells/ml) onto plates with a fixed concentration of MF (30 ng/ml), GdA, or RAD, as indicated, and were photographed after 48 hours in the dark at 30°C. (C) Genetic compromise of Hsp90 expression reduces MF tolerance in an MIC assay. The assay was performed and analyzed as in part A. (D) Genetic compromise of Hsp90 expression reduces MF tolerance on solid rich medium (YPD). The assay was performed and analyzed as in part B except plates were photographed after 72 hours.
Figure 1 Hsp90 plays a crucial role in echinocandin tolerance of Candida albicans. (A) Pharmacological inhibition of Hsp90 with GdA or RAD reduces MF tolerance of C. albicans laboratory strains in an MIC assay. Assays were done in synthetic defined medium at 30°C for 72 hours. Optical densities were averaged for duplicate measurements and normalized relative to MF-free controls (see colour bar). (B) Pharmacological inhibition of Hsp90 reduces MF tolerance on solid rich medium (YPD). Cells were spotted in fivefold dilutions (from 1×106 cells/ml) onto plates with a fixed concentration of MF (30 ng/ml), GdA, or RAD, as indicated, and were photographed after 48 hours in the dark at 30°C. (C) Genetic compromise of Hsp90 expression reduces MF tolerance in an MIC assay. The assay was performed and analyzed as in part A. (D) Genetic compromise of Hsp90 expression reduces MF tolerance on solid rich medium (YPD). The assay was performed and analyzed as in part B except plates were photographed after 72 hours.CC BY · PubMed Central
Figure 2 Compromising calcineurin function phenocopies compromising Hsp90 function. Deletion of either the catalytic subunit of calcineurin, CNA1, or the regulatory subunit of calcineurin, CNB1, abrogates MF tolerance. Pharmacological inhibition of calcineurin with either CsA or FK506 also abrogates MF tolerance. The assay was performed and analyzed as in Figure 1A.
Figure 2 Compromising calcineurin function phenocopies compromising Hsp90 function. Deletion of either the catalytic subunit of calcineurin, CNA1, or the regulatory subunit of calcineurin, CNB1, abrogates MF tolerance. Pharmacological inhibition of calcineurin with either CsA or FK506 also abrogates MF tolerance. The assay was performed and analyzed as in Figure 1A.CC BY · PubMed Central
Figure 3 Inhibition of Hsp90 or calcineurin creates a fungicidal combination with MF. An MIC assay with four-fold MF dilutions was performed in YPD with or without either the Hsp90 inhibitor GdA or the calcineurin inhibitor CsA and incubated for 72 hours at 30°C. Cells from the MIC assay were spotted onto solid YPD medium and incubated at 30°C for 48 hours.
Figure 3 Inhibition of Hsp90 or calcineurin creates a fungicidal combination with MF. An MIC assay with four-fold MF dilutions was performed in YPD with or without either the Hsp90 inhibitor GdA or the calcineurin inhibitor CsA and incubated for 72 hours at 30°C. Cells from the MIC assay were spotted onto solid YPD medium and incubated at 30°C for 48 hours.CC BY · PubMed Central
Figure 4 Calcineurin is an Hsp90 client protein in C. albicans. (A) Hsp90 and calcineurin physically interact as measured by co-immunoprecipitation of Hsp90 with Cna1-HisFLAG. Immunoprecipitation of HisFLAG-tagged Cna1 with anti-FLAG M2 affinity agarose, co-purifies Hsp90. Hsp90 was not immunoprecipitated by anti-FLAG M2 affinity agarose in control cells harboring untagged Cna1. (B) Hsp90 and calcineurin physically interact as measured by the reciprocal co-immunoprecipitation of Cna1-HisFLAG with Hsp90-TAP. Immunoprecipitation of Hsp90-TAP with IgG agarose, co-purifies Cna1-HisFLAG. Cna1-HisFLAG was not immunoprecipitated by IgG agarose in control cells harboring untagged Hsp90. (C) Calcineurin activation is blocked by pharmacological inhibition of Hsp90. A strain harboring a UTR2p-lacZ construct was incubated in rich medium with no treatment (U) or with 0.2 M CaCl2 (Ca) to activate calcineurin. The impact of the calcineurin inhibitor CsA (10 µM), or the Hsp90 inhibitors GdA (5 µM) or RAD (5 µM) on calcineurin activation was determined by measurement of β-galactosidase activity. Data are means±standard deviations for triplicate samples. (D) Genetic reduction of Hsp90 levels results in depletion of calcineurin. All strains shown in this panel have one allele of Cna1-HisFLAG in addition to the indicated genotype. Even when fully induced in the maltose, expression of Hsp90 from the MAL2 promoter is not as strong as from the native promoter, while glucose results in further reduction of Hsp90 expression. This reduction of Hsp90 levels is accompanied by depletion of calcineurin. Top two panels, immune blot analysis of Hsp90 levels relative to the histone H3 loading control (5 µg protein loaded per well). Bottom two panels, immune blot analysis of Cna1-HisFLAG relative to the histone H3 loading control (50 µg protein loaded per well).
Figure 4 Calcineurin is an Hsp90 client protein in C. albicans. (A) Hsp90 and calcineurin physically interact as measured by co-immunoprecipitation of Hsp90 with Cna1-HisFLAG. Immunoprecipitation of HisFLAG-tagged Cna1 with anti-FLAG M2 affinity agarose, co-purifies Hsp90. Hsp90 was not immunoprecipitated by anti-FLAG M2 affinity agarose in control cells harboring untagged Cna1. (B) Hsp90 and calcineurin physically interact as measured by the reciprocal co-immunoprecipitation of Cna1-HisFLAG with Hsp90-TAP. Immunoprecipitation of Hsp90-TAP with IgG agarose, co-purifies Cna1-HisFLAG. Cna1-HisFLAG was not immunoprecipitated by IgG agarose in control cells harboring untagged Hsp90. (C) Calcineurin activation is blocked by pharmacological inhibition of Hsp90. A strain harboring a UTR2p-lacZ construct was incubated in rich medium with no treatment (U) or with 0.2 M CaCl2 (Ca) to activate calcineurin. The impact of the calcineurin inhibitor CsA (10 µM), or the Hsp90 inhibitors GdA (5 µM) or RAD (5 µM) on calcineurin activation was determined by measurement of β-galactosidase activity. Data are means±standard deviations for triplicate samples. (D) Genetic reduction of Hsp90 levels results in depletion of calcineurin. All strains shown in this panel have one allele of Cna1-HisFLAG in addition to the indicated genotype. Even when fully induced in the maltose, expression of Hsp90 from the MAL2 promoter is not as strong as from the native promoter, while glucose results in further reduction of Hsp90 expression. This reduction of Hsp90 levels is accompanied by depletion of calcineurin. Top two panels, immune blot analysis of Hsp90 levels relative to the histone H3 loading control (5 µg protein loaded per well). Bottom two panels, immune blot analysis of Cna1-HisFLAG relative to the histone H3 loading control (50 µg protein loaded per well).CC BY · PubMed Central
Figure 5 Echinocandins and azoles activate calcineurin-dependent stress responses. (A) The echinocandin MF activates calcineurin. A strain harboring a UTR2p-lacZ construct was incubated in rich medium without treatment (U) or with 30 ng/ml MF in combination with the calcineurin inhibitor CsA (10 µM) or the Hsp90 inhibitor RAD (5 µM), as indicated, for 8 hours. Data are means±standard deviations for triplicate samples. (B) The azole fluconazole (FL) activates calcineurin in an Hsp90-dependent manner. A strain harboring a UTR2p-lacZ construct was incubated in rich medium without treatment (U) or with 16 µg/ml FL in combination with the calcineurin inhibitor CsA (10 µM) or the Hsp90 inhibitor RAD (5 µM), as indicated, for 24 hours.
Figure 5 Echinocandins and azoles activate calcineurin-dependent stress responses. (A) The echinocandin MF activates calcineurin. A strain harboring a UTR2p-lacZ construct was incubated in rich medium without treatment (U) or with 30 ng/ml MF in combination with the calcineurin inhibitor CsA (10 µM) or the Hsp90 inhibitor RAD (5 µM), as indicated, for 8 hours. Data are means±standard deviations for triplicate samples. (B) The azole fluconazole (FL) activates calcineurin in an Hsp90-dependent manner. A strain harboring a UTR2p-lacZ construct was incubated in rich medium without treatment (U) or with 16 µg/ml FL in combination with the calcineurin inhibitor CsA (10 µM) or the Hsp90 inhibitor RAD (5 µM), as indicated, for 24 hours.CC BY · PubMed Central
Figure 6 The calcineurin-dependent transcription factor Crz1 plays a partial role in echinocandin tolerance. (A) Homozygous deletion of CRZ1 partially reduces tolerance to MF in an MIC assay. The assay was performed and analyzed as in Figure 1A. (B) Homozygous deletion of CRZ1 partially reduces tolerance to MF on solid rich medium (YPD). Complementation with a wild-type CRZ1 allele restores tolerance. The assay was performed and analyzed as in Figure 1B.
Figure 6 The calcineurin-dependent transcription factor Crz1 plays a partial role in echinocandin tolerance. (A) Homozygous deletion of CRZ1 partially reduces tolerance to MF in an MIC assay. The assay was performed and analyzed as in Figure 1A. (B) Homozygous deletion of CRZ1 partially reduces tolerance to MF on solid rich medium (YPD). Complementation with a wild-type CRZ1 allele restores tolerance. The assay was performed and analyzed as in Figure 1B.CC BY · PubMed Central
Figure 7 Hsp90 and calcineurin mediate echinocandin resistance of isolates that acquired Fks1 mutations during selection in vitro or in a human host. Pharmacological inhibition of Hsp90 or calcineurin reduces MF tolerance of a laboratory strain (SC5314), a laboratory derived Fks1 F641S mutant (C42), and a clinical isolate harboring the same Fks1 mutation (DPL15). Checkerboards were performed in synthetic defined medium and incubated at 30°C for 72 hours. Data was analyzed as in Figure 1A.
Figure 7 Hsp90 and calcineurin mediate echinocandin resistance of isolates that acquired Fks1 mutations during selection in vitro or in a human host. Pharmacological inhibition of Hsp90 or calcineurin reduces MF tolerance of a laboratory strain (SC5314), a laboratory derived Fks1 F641S mutant (C42), and a clinical isolate harboring the same Fks1 mutation (DPL15). Checkerboards were performed in synthetic defined medium and incubated at 30°C for 72 hours. Data was analyzed as in Figure 1A.CC BY · PubMed Central
Figure 8 Genetic compromise of C. albicans HSP90 renders micafungin (MF) more efficacious in a murine model of disseminated disease. CD1 mice were infected with an inoculum of 100 µl of 2×106 colony forming units (CFU)/ml of a strain expressing wild-type HSP90 levels or a strain with its only HSP90 allele regulated by tetO. MF was administered at 0.2 mg/kg intraperitoneally at one-hour post infection and then daily, as indicated. One asterisk indicates P<0.05; two asterisks indicate P<0.001 (ANOVA, Bonferroni's Multiple Comparison Test).
Figure 8 Genetic compromise of C. albicans HSP90 renders micafungin (MF) more efficacious in a murine model of disseminated disease. CD1 mice were infected with an inoculum of 100 µl of 2×106 colony forming units (CFU)/ml of a strain expressing wild-type HSP90 levels or a strain with its only HSP90 allele regulated by tetO. MF was administered at 0.2 mg/kg intraperitoneally at one-hour post infection and then daily, as indicated. One asterisk indicates P<0.05; two asterisks indicate P<0.001 (ANOVA, Bonferroni's Multiple Comparison Test).CC BY · PubMed Central
Figure 9 Divergence of Hsp90 and calcineurin's role in echinocandin tolerance in S. cerevisiae. (A) Hsp90 and calcineurin physically interact in S. cerevisiae as measured by co-immunoprecipitation of Hsp90 (encoded by HSC82 and HSP82) with Cna1-TAP. Immunoprecipitation of TAP-tagged Cna1 with IgG agarose co-purifies Hsp90. Hsp90 was not immunoprecipitated by IgG agarose in control cells harboring untagged Cna1. (B) Calcineurin activation is blocked by pharmacological inhibition of Hsp90. A strain harboring a CDRE-lacZ construct was incubated in synthetic defined medium with no treatment (U) or with 0.2 M CaCl2 (Ca) to activate calcineurin. The impact of the calcineurin inhibitor FK506 (1 µg/ml) or the Hsp90 inhibitor GdA (5 µM) on calcineurin activation was determined by measurement of β-galactosidase activity. Data are means±standard deviations for triplicate samples. (C) The echinocandin MF and the azole FL activate calcineurin. A strain harboring a CDRE-lacZ construct was incubated in synthetic defined medium without treatment (U), with 30 ng/ml MF for 8 hours, or with 16 µg/ml FL for 24 hours. Data are means±standard deviations for triplicate samples. (D) Compromising calcineurin or Hsp90 has minimal effect on tolerance to MF in S. cerevisiae in an MIC assay. The effects of CsA are not due to inhibition of calcineurin given that genetic compromise of calcineurin by deletion of the regulatory subunit encoded by CNB1 or by deletion of the catalytic subunit encoded by CNA1 and CNA2 has no impact on MF tolerance. The assay was performed in synthetic defined medium at 25°C and was analyzed as in Figure 1A.
Figure 9 Divergence of Hsp90 and calcineurin's role in echinocandin tolerance in S. cerevisiae. (A) Hsp90 and calcineurin physically interact in S. cerevisiae as measured by co-immunoprecipitation of Hsp90 (encoded by HSC82 and HSP82) with Cna1-TAP. Immunoprecipitation of TAP-tagged Cna1 with IgG agarose co-purifies Hsp90. Hsp90 was not immunoprecipitated by IgG agarose in control cells harboring untagged Cna1. (B) Calcineurin activation is blocked by pharmacological inhibition of Hsp90. A strain harboring a CDRE-lacZ construct was incubated in synthetic defined medium with no treatment (U) or with 0.2 M CaCl2 (Ca) to activate calcineurin. The impact of the calcineurin inhibitor FK506 (1 µg/ml) or the Hsp90 inhibitor GdA (5 µM) on calcineurin activation was determined by measurement of β-galactosidase activity. Data are means±standard deviations for triplicate samples. (C) The echinocandin MF and the azole FL activate calcineurin. A strain harboring a CDRE-lacZ construct was incubated in synthetic defined medium without treatment (U), with 30 ng/ml MF for 8 hours, or with 16 µg/ml FL for 24 hours. Data are means±standard deviations for triplicate samples. (D) Compromising calcineurin or Hsp90 has minimal effect on tolerance to MF in S. cerevisiae in an MIC assay. The effects of CsA are not due to inhibition of calcineurin given that genetic compromise of calcineurin by deletion of the regulatory subunit encoded by CNB1 or by deletion of the catalytic subunit encoded by CNA1 and CNA2 has no impact on MF tolerance. The assay was performed in synthetic defined medium at 25°C and was analyzed as in Figure 1A.CC BY · PubMed Central

Verification

Claims the paper makes

19 Valid · 3 Not valid · 19 Not checked · 75 Own results and interpretations

56 more claims · 1 with their cited sources checked

Create a free account to see all 116 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 35
  • It may state two separate claims as one. 27
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

26 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 60 references

Cited by

See all 364

Metadata

Authors
Singh, S. D., Robbins, N., Zaas, A. K., Schell, W. A., Perfect, J. R., & Cowen, L. E.
Affiliations
  • University of Toronto (CA)
  • Duke Medical Center (US)
Corresponding author
Cowen, Leah E.
Venue
PLoS Pathogens
Published
2009-07-31
Volume
5
Issue
7
Pages
e1000532
ISSN
  • 1553-7366 (ISSN-L)
  • 1553-7374
OpenAlex
W2087273774
Cited by
362
References
60
Citations by year
2026: 19 · 2025: 26 · 2024: 14 · 2023: 25 · 2022: 24 · 2021: 28 · 2020: 23 · 2019: 18 · 2018: 18 · 2017: 18 · 2016: 20 · 2015: 16 · 2014: 32 · 2013: 25 · 2012: 23
FWCI
12.82
Type
journal article
Language
en
Open access
Locations
  • PLoS Pathogens (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
Funders
  • Burroughs Wellcome Fund
  • University of Toronto
  • National Institutes of Health
  • Canadian Institutes of Health Research (MOP-86452)
  • Natural Sciences and Engineering Research Council of Canada
  • National Institute of Allergy and Infectious Diseases (AI 73896, R56AI028388, AI28388, R01AI073896, R01AI028388, K08AI065837)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
Keywords
HSP90, calcineurin, Candida albicans, echinocandin resistance, antifungal resistance, candidiasis, Hsp90 client proteins, Crz1, calcineurin signaling, molecular chaperones, fungal cell wall biosynthesis, HSP90 inhibition, combination antifungal therapy, systemic candidiasis
MeSH terms
Micafungin, Analysis of Variance, Animals, Antifungal Agents, Azoles, Candida albicans, Candidiasis, Disease Models, Animal, DNA-Binding Proteins, Fungal Proteins, Male, Stress, Physiological, Transcription Factors, HSP90 Heat-Shock Proteins, Calcineurin, Drug Resistance, Fungal, Mice, Echinocandins, Lipopeptides

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-09, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-09 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Hsp90 Governs Echinocandin Resistance in the Pathogenic Yeast Candida albicans via Calcineurin. https://app.cochat.ai/papers/10.1371/journal.ppat.1000532
The paper
Singh, S. D., Robbins, N., Zaas, A. K., Schell, W. A., Perfect, J. R., & Cowen, L. E. (2009). Hsp90 Governs Echinocandin Resistance in the Pathogenic Yeast Candida albicans via Calcineurin. PLoS Pathogens. https://doi.org/10.1371/journal.ppat.1000532

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.